INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice - Takeaways - MDSpire

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • By

  • Sameer Sharma

  • Lixian Chen

  • Tianhao Zhou

  • Meenakshi Chawla

  • Anita Ganjoo

  • Shunichiro Okada

  • Salvatore Alesci

  • Krishnan Nandabalan

  • Heather Francis

  • June 9, 2026

  • 0 min

Share

  • 1

    Mast cells play a significant role in autoimmune diseases, particularly in chronic liver diseases like primary sclerosing cholangitis (PSC).

  • 2

    INVA8001, a selective chymase inhibitor, was tested in Mdr2 knockout mice to evaluate its effects on liver inflammation and fibrosis associated with PSC.

  • 3

    Treatment with INVA8001 resulted in reduced chymase activity, inflammation, and fibrosis in Mdr2−/− mice, indicating its potential therapeutic effects.

  • 4

    Liver biopsies from PSC patients showed increased chymase-positive cells compared to non-diseased controls, highlighting chymase's role in PSC pathogenesis.

  • 5

    The findings suggest that chymase inhibition may offer a multifaceted approach to treating PSC and other mast cell-related disorders.

Original Source(s)

INVA8001, a novel and highly selective chymase inhibitor, ameliorates liver inflammation, fibrosis, and hyperplasia in Mdr2 knockout mice

  • by Sameer Sharma, Lixian Chen, Tianhao Zhou, Meenakshi Chawla, Anita Ganjoo, Shunichiro Okada, Salvatore Alesci, Krishnan Nandabalan, Heather Francis

  • June 9, 2026

Related Content

Free Fatty acid-induced disruption of hepatic vitamin D metabolism impairs bone homeostasis in an in vitro 3D human liver–bone model

STAT investigates the epidemic killing 178,000 Americans a year

Borderline Liver Enzyme Patterns and Their Metabolic–Inflammatory Signatures: An Observational Outpatient Study